Physician profile
Patrick Michael Doty
NPI 1467973800
$3,161.40
in general payments reported to CMS, 2019-2025
13 companies · $2,196 in 2025
The $2,196 reported for 2025 was more than what 93% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $55.19 · 2021: $131 · 2022: $204 · 2023: $131 · 2024: $172 · 2025: $2,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,800 · Food and Beverage: $613 · Entertainment: $85.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,800.00 |
| Food and Beverage | $613.11 |
| Entertainment | $85.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,941.48 | 2019-2025 | Proclear Contact Lens |
| Abb Con-Cise Optical Group LLC | $336.27 | 2021-2025 | Contact Lens, Spectacle Lenses |
| Visioneering Technologies, INC. | $290.68 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $141.21 | 2024 | Xdemvy |
| Maculogix, INC. | $114.40 | 2019 | |
| Optos, INC. | $85.88 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $85.30 | 2021-2023 | Total30 |
| Novartis Pharmaceuticals Corporation | $75.82 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $20.50 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb Americas INC. | $18.97 | 2023 | |
| Oyster Point Pharma, INC. | $18.46 | 2022 | |
| Lkc Technologies, INC. | $13.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Doty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.